Huons Global Q1 2026: Operating Profit 9.2B Won, Quarterly Dividend 200 Won

Consolidated Q1 2026: Revenue 197B won, Operating profit 9.2B won, Net profit attributable to parent 6.1B won (EPS 499 won)
Quarterly dividend of 200 won per share (total 2.44B won), record date May 27, 2026, payment June 16
Medium-term dividend policy: Target annual DPS 800 won for 2026-2028, with 5-30% annual increase
On May 13, 2026, exercised buyback option for botulinum toxin subsidiary shares, paying 17.83B won (contingent liability resolved)
Ongoing litigation: violation of Pharmaceutical Affairs Act and patent lawsuit (risk)
Debt ratio 42.5%, net debt 65.4B won, cash 197.9B won (healthy financial position)
R&D expense 16B won (8.1% of sales)